Susquehanna Fundamental Investments LLC Makes New Investment in Bruker Co. (NASDAQ:BRKR)

Susquehanna Fundamental Investments LLC purchased a new position in Bruker Co. (NASDAQ:BRKR - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 198,335 shares of the medical research company's stock, valued at approximately $11,626,000. Susquehanna Fundamental Investments LLC owned about 0.13% of Bruker at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of BRKR. Eagle Bay Advisors LLC grew its position in Bruker by 2,324.1% in the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company's stock worth $41,000 after purchasing an additional 674 shares during the period. UMB Bank n.a. lifted its holdings in Bruker by 37.5% in the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock valued at $53,000 after acquiring an additional 248 shares during the period. Quadrant Capital Group LLC grew its holdings in Bruker by 18.2% during the fourth quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock valued at $75,000 after purchasing an additional 196 shares during the period. GAMMA Investing LLC increased its holdings in Bruker by 47.5% in the 4th quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company's stock valued at $75,000 after acquiring an additional 412 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its stake in Bruker by 41.5% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,330 shares of the medical research company's stock worth $78,000 after purchasing an additional 390 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors.

Bruker Stock Down 1.8 %

NASDAQ:BRKR traded down $0.71 during trading hours on Thursday, reaching $39.35. The company's stock had a trading volume of 1,793,049 shares, compared to its average volume of 1,527,175. The stock has a 50 day moving average price of $42.51 and a two-hundred day moving average price of $52.27. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The company has a market capitalization of $5.96 billion, a P/E ratio of 51.78, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. Bruker Co. has a 12 month low of $34.10 and a 12 month high of $80.02.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. Equities analysts predict that Bruker Co. will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Monday, March 17th were paid a dividend of $0.05 per share. The ex-dividend date was Monday, March 17th. This represents a $0.20 annualized dividend and a yield of 0.51%. Bruker's dividend payout ratio (DPR) is 26.32%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on BRKR shares. Stifel Nicolaus decreased their target price on Bruker from $70.00 to $57.00 and set a "hold" rating on the stock in a research report on Friday, February 14th. Guggenheim restated a "buy" rating on shares of Bruker in a report on Monday, February 24th. Citigroup reduced their target price on shares of Bruker from $75.00 to $50.00 and set a "buy" rating on the stock in a research note on Monday, April 7th. Barclays cut their target price on Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Finally, Wells Fargo & Company cut their price objective on Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a research report on Thursday, April 17th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $65.00.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.